Inclusion complex of tamibarotene with hydroxypropyl-β-cyclodextrin: Preparation, characterization, in-vitro and in-vivo evaluation

Asian Journal of Pharmaceutical Sciences

Volumn 12, Issue 2, 2017, Pages 187-192

  Yang, Ying ^a   Gao, Jinhua ^a   Ma, Xiaoyu ^a   Huang, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bio availability; Hydroxypropyl cyclodextrin; Solubility; Tamibarotene

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; TAMIBAROTENE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FEMALE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 85008516841     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2016.08.009     Document Type: Article

References (14)

1. [1] Jin, Y., Wang, L.Y., Liu, D.X., Tamibarotene modulates the local immune response in experimental periodontitis. Int Immunopharmacol 23 (2014), 537–545.
2. [2] Miwako, I., Kagechika, H., Tamibarotene. Drugs Today (Barc) 43 (2007), 563–568.
3. [3] Mario, J., Natascia, M., Katalin, E., et al. Comparative analysis of binary and ternary cyclodextrin complexes with econazole nitrate in solution and in solid state. J Pharm Biomed Anal 91 (2014), 81–91.
4. [4] Hiroshi, F., Madoka, N., Naoko, Y., et al. Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull 35 (2012), 1206–1212.
5. [5] Liu, M., Chen, A.J., Wang, Y., et al. Improved solubility and stability of 7-hydroxy-4-methylcoumarin at different temperatures and pH values through complexation with sulfobutyl ether-b-cyclodextrin. Food Chem 168 (2015), 270–275.
6. [6] Sakai, H., Horiguchi, M., Ozawa, C., et al. Pulmonary administration of Am80 regenerates collapsed alveoli. J Control Release 196 (2014), 154–160.
7. [7] Kanai, F., Obi, S., Fujiyama, S., et al. An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. Hepatol Int 8 (2013), 94–103.
8. [8] Okusaka, T., Ueno, H., Ikeda, M., et al. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 41 (2011), 542–552.
9. [9] Fu, J., Zhang, J.Y., Wang, F.S., Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 8 (2014), 1–3.
10. [10] Shimizu, M., Takai, K., Moriwaki, H., Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor α is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100 (2009), 369–374.
11. [11] Jozsef, S., Utilization of cyclodextrins in industrial products and processes. J Mater Chem 7 (1997), 575–587.
12. [12] Larsen, K.L., Large cyclodextrins. J Incl Phenom Macrocycl Chem 43 (2002), 1–13.
13. [13] Gould, S., Scott, R.C., 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 43 (2005), 1451–1459.
14. [14] Lajos, S., Jozsef, S., Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36 (1999), 17–28.